Ocuphire Pharma Investor Updates

P 32 2021 to 2022 Ocuphire Cadence of Milestones Multiple Data Catalysts On Path To NDA(s) 2020 Completion of APX3330 License ARVO 2020 Presentation for MIRA-1 & ORION-1 FDA EOP2 Meeting May 2020 Completion of Transaction (Nasdaq: OCUP) and concurrent $20M financing Initiate Phase 3 RM Trial Initiate Phase 3 NVD Trial Complete Nyxol Market Research Journal Publications 1H 2021 Enrollment of Phase 3 RM Trial Initiate Phase 2 Presbyopia Trial Report Positive Phase 3 Data for RM Initiate Phase 2 DR/DME Trial Enrollment of Phase 2 Presbyopia Trial New Patent Claims Closed $15M registered direct offering Report Positive Phase 2 Data for Presbyopia 2H 2021 *Additional Studies for NVD and DR based on Data Readouts ASCRS 2021 Presentation for MIRA-2 & VEGA-1 Initiate 2nd P3 RM and Pediatric RM trial for NDA O Enrollment of Phase 3 NVD Trial Report Phase 3 Data for NVD Enrollment of Phase 2 DR/DME Trial Industry Conferences & Publications Manufacture 3xRegistration Batches for Nyxol Blow-Fill- Seal (BFS) Eye Drops Complete 6-month Rabbit Tox Study 2022* Report 2nd Ph3 RM Trial Report Pediatric RM trial Report Phase 2 Data for DR/DME Initiate 2 Phase 3 Presbyopia Trials Initiate Chronic Ph3 Safety Trial (Nyxol/LDP) Complete 1 year CMC stability on 3xreg batches Submit Nyxol NDA filing for RM in late 2022 Manufacture Commercial Batches of Nyxol Eye Drop Ongoing partnering discussions with leading ophthalmic companies (including European and Asian players) 2023* Report Phase 3 Data for Presbyopia Trials Potential NDA for Nyxol in RM Potential Commercial Launch of Nyxol in US Submit NDA filing for Nyxol for Presbyopia in 2023 Ocuphire PHARMA

View entire presentation